Immunotherapy in the Age of COVID-19
Immunotherapy has become a mainstay in the treatment of non-small cell lung cancer, but more recently, it has moved into the small cell lung cancer space, too. In this episode of “The Vitals,” Beth Sandy, NP, a nurse practitioner at the University of Pennsylvania Abramson Cancer Center, discusses the immune-related adverse events (irAEs) that nurses need to be aware of when treating patients with these agents.
Sandy also discussed how some irAEs, such as difficulty breathing — which is more common in lung cancer than other tumor types – can be similar to coronavirus disease 2019 (COVID-19) symptoms. She offered advice on how to determine which it is in this unprecedented time in oncology nursing.
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
September 19th 2024The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.
